Roche Looks To Fuel Early-stage Partnerships In China While Shunning Branded Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss pharma giant also sees more start-ups of interest, particularly ones founded by China returnees who have worked for Western pharmaceutical companies, Roche global BD head says.
You may also be interested in...
Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)
When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership
Roche Global Licensing Director Stella Xu and Business Development Director Frank Grams On Seeking More Innovation In China And Korea: An Interview With PharmAsia News (Part 2 of 2)
Roche recently expanded its investment in innovation in Asia by opening its fourth Global Partnering office in Shanghai. Roche Global Licensing Director Stella Xu and Business Development Director Frank Grams sat down with PharmAsia News' Shanghai Bureau to talk about the mission of the newly established partnering site and Roche's partnering strategies in Asia.